Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma (MREO) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Mereo BioPharma (MREO) over the last 5 years, with Q3 2025 value amounting to 0.87.

  • Mereo BioPharma's Equity Ratio rose 636.08% to 0.87 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.87, marking a year-over-year increase of 636.08%. This contributed to the annual value of 0.8 for FY2024, which is 502.15% up from last year.
  • Mereo BioPharma's Equity Ratio amounted to 0.87 in Q3 2025, which was up 636.08% from 0.87 recorded in Q2 2025.
  • Mereo BioPharma's Equity Ratio's 5-year high stood at 0.88 during Q1 2025, with a 5-year trough of 0.64 in Q2 2022.
  • Over the past 5 years, Mereo BioPharma's median Equity Ratio value was 0.8 (recorded in 2024), while the average stood at 0.78.
  • Per our database at Business Quant, Mereo BioPharma's Equity Ratio crashed by 461.52% in 2022 and then soared by 1482.77% in 2025.
  • Over the past 5 years, Mereo BioPharma's Equity Ratio (Quarter) stood at 0.7 in 2021, then fell by 4.62% to 0.66 in 2022, then rose by 14.45% to 0.76 in 2023, then grew by 5.02% to 0.8 in 2024, then increased by 8.92% to 0.87 in 2025.
  • Its Equity Ratio stands at 0.87 for Q3 2025, versus 0.87 for Q2 2025 and 0.88 for Q1 2025.